Clinical Trials Logo

Carcinoma, Squamous Cell clinical trials

View clinical trials related to Carcinoma, Squamous Cell.

Filter by:

NCT ID: NCT06184841 Completed - Clinical trials for Esophageal Squamous Cell Carcinoma

HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma

Start date: June 18, 2020
Phase: Phase 1
Study type: Interventional

Patients with liver metastasis from esophagus squamous (ESC) are usually offered systemic therapy. However, for those with predominant liver disease or failure of system therapy, local liver management becomes an option. This prospective single center study aimed to evaluate the efficacy and adverse events of hepatic arterial infusion chemotherapy (HAIC) using percutaneous catheter placement techniques for liver metastases from esophagus squamous (ESC).

NCT ID: NCT06165094 Completed - Esophageal Cancer Clinical Trials

Effect of Cervical Paraesophageal Lymph Node Metastasis Versus Supraclavicular Lymph Node Metastasis on the Overall Survival of Patients With Thoracic Esophageal Squamous Cell Carcinoma: An Observational Study

ECPLNMvsSLNM
Start date: January 1, 2009
Phase:
Study type: Observational

The goal of this observational study is to learn about in health conditions of ESCC. The main question[s] it aims to answer are: •Lymph node metastasis(LNM) in cervical paraesophageal or supraclavicular which influence OS more. Participants will describe the main status quo after surgery Researchers will compare Lymph node metastasis(LNM) in cervical paraesophageal and supraclavicular to see if dead.

NCT ID: NCT06062602 Completed - Clinical trials for Head and Neck Squamous Cell Carcinoma

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

Start date: July 26, 2021
Phase: Early Phase 1
Study type: Interventional

This is a multi-center, open-label Phase 0 substudy designed to study the localized pharmacodynamics (PD) of TAK-676 alone or in combination with Carboplatin, 5-FU, or Paclitaxel within the tumor microenvironment (TME) when administered intratumorally in microdose quantities via the CIVO device in patients diagnosed with Head and Neck Squamous Cell Carcinoma presenting with a surface accessible solid tumor for which there is a scheduled surgical intervention. This substudy is a cohort of the PBI-MST-01 Master Protocol.

NCT ID: NCT05941676 Completed - Clinical trials for Head and Neck Cancer

Prognostic Immune Biomarkers in HNSCC

Start date: June 1, 2020
Phase:
Study type: Observational

Evaluation of the prognostic potential of tumor-infiltrating lymphocytes and PD-L1 expression in non-metastatic squamous cell carcinoma of the head and neck

NCT ID: NCT05918224 Completed - Clinical trials for Head and Neck Squamous Cell Carcinoma

Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of Streptococcus salivarius K12 for prevention and treatment of oral mucositis in patients undergoing radiotherapy for malignant head and neck tumors.

NCT ID: NCT05841966 Completed - Clinical trials for Cancer of Unknown Primary Site

Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary

OP-CUP
Start date: February 21, 2023
Phase: N/A
Study type: Interventional

Adult patients suspected of Squamous Cell Carcinoma of Unknown Primary (SCCUP) will be prospectively enrolled at a tertiary head & neck cancer center at Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. All patients will undergo Magnetic Resonance Imaging (MRI) and Positron Emission Tomography-Computerized Tomography (PET-CT) prior to examination in general anesthesia. During general anesthesia, Intraoperative Transoral Ultrasound (ITUS) will be performed prior to panendoscopy. Detected tumors will be registered with specified oropharyngeal sub-locations. Blinded to ITUS, a consultant head & neck surgeon will perform panendoscopy. After examination, the surgeon is unblinded to ultrasound results. Final histopathology results from location-specified biopsies performed will be used as reference standard. The overall detection rate will be compared between ITUS, panendoscopy, PET-CT and MRI with sensitivity and specificity analysis. Oropharynx sub-location specific detection rate of ITUS vs. panendoscopy will be compared with logistic regression analysis.

NCT ID: NCT05821179 Completed - Clinical trials for Oral Squamous Cell Carcinoma

Salivary LINC00657 as a Diagnostic Biomarker for Oral Squamous Cell Carcinoma

Start date: January 1, 2022
Phase:
Study type: Observational

This study was designed to verify the role of salivary LINC00657 as a diagnostic marker in oral squamous cell carcinoma (OSCC) patients as compared to oral lichen planus (OLP) (as an example of oral potentially malignant lesions) and normal individuals, and to show its relation to miR-106a. A total of 36 participants were included.

NCT ID: NCT05802290 Completed - Clinical trials for Squamous Cell Carcinoma of Head and Neck

NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN

NIVACTOR
Start date: November 27, 2017
Phase: Phase 3
Study type: Interventional

Subjects will receive treatment with nivolumab monotherapy at 240mg flat dose as a 30 minute IV infusion on Day 1 of a treatment cycle every 2 weeks (14 days) until confirmed progression of disease, unacceptable toxicity, death or withdrawal of consent. This study is designed to better evaluate the safety profile of nivolumab in a large series of patients with Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck. The primary endpoint of this study is the incidence of high-grade (CTCAE v 4.03 Grade 3 or higher), treatment-related, select adverse events.

NCT ID: NCT05792228 Completed - Clinical trials for Squamous Cell Carcinoma of Head and Neck

A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and Vomiting

Start date: April 2, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to investigate the effect of a nurse-led standardized intervention on chemotherapy induced nausea and vomiting (CINV) in patients with head and neck squamous cell carcinoma. The main questions it aims to answer are: (1) what's the best practice to enhance the management of CINV; (2) how's the effect of the nurse-led standardized intervention on CINV in the patients treated with cisplatin-based chemotherapy. Participants in the intervention group will receive evidence-based, nurse-led standardized management of CINV, including nurse-led risk assessment, education on prevention and control of CINV, antiemetics following guidelines, dietary strategies, relaxation therapy, and follow up. Participants in the control group will receive routine care of CINV. The incidence and occurrence degree of CINV and its influence on patients' quality of life will be compared between the two groups.

NCT ID: NCT05708209 Completed - Clinical trials for Oral Squamous Cell Carcinoma

The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124

Start date: November 1, 2022
Phase:
Study type: Observational

Objective: is to determine the diagnostic accuracy of lncRNA MALAT1 as a potential salivary biomarker of OSCC as well as assessment of the salivary expression level of miRNA 124 which is targeted by MALAT1. Materials and Methods: Saliva Samples were collected for the quantitative determination of salivary "MALAT1 and mi RNA -124" using quantitative Real-time Polymerase Chain Reaction technique for the two study groups, Group A: 20 patients with a diagnosis suggestive of OSCC and Group B: 20 age-and-sex-matched healthy individuals, as normal controls.